nrc health (nasdaq:nrcia and nrcib) has helped healthcare organizations illuminate and improve the moments that matter to patients, residents, physicians, nurses, and staff for 35 years. our empathetic heritage, proprietary methods, and holistic approach enable our partners to better understand the people they care for, and in turn, design experiences that inspire loyalty and trust. for more information call 800-388-4264, write to info@nrchealth.com, or visit www.nrchealth.com.
Company profile
Ticker
NRC
Exchange
Website
CEO
Michael Hays
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
SEC CIK
Corporate docs
Subsidiaries
National Research Corporation Canada ...
IRS number
470634000
NRC stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
11 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Results of Operations and Financial Condition
13 Feb 24
8-K
National Research Corporation Elevates Leadership Team to Seize Growth Opportunity
17 Jan 24
8-K
Departure of Directors or Certain Officers
2 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
National Research Corporation Announces Third Quarter 2023 Results
8 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
Results of Operations and Financial Condition
3 Aug 23
8-K
Entry into a Material Definitive Agreement
22 Jun 23
Transcripts
NRC
Earnings call transcript
2023 Q4
14 Feb 24
NRC
Earnings call transcript
2023 Q3
8 Nov 23
NRC
Earnings call transcript
2023 Q2
2 Aug 23
NRC
Earnings call transcript
2023 Q1
3 May 23
NRC
Earnings call transcript
2022 Q4
15 Feb 23
NRC
Earnings call transcript
2022 Q3
3 Nov 22
NRC
Earnings call transcript
2022 Q2
6 Aug 22
NRC
Earnings call transcript
2022 Q1
7 May 22
NRC
Earnings call transcript
2021 Q4
9 Feb 22
NRC
Earnings call transcript
2021 Q4
9 Feb 22
Latest ownership filings
3
Linda Stacy
3 Apr 24
4
JOHN N NUNNELLY
29 Mar 24
SC 13G/A
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
8 Mar 24
SC 13D/A
Common Property Trust
5 Mar 24
4
Change in insider ownership
5 Mar 24
SC 13G/A
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
13 Feb 24
3
Jason Hahn
22 Jan 24
3
Christophe Louvion
22 Jan 24
3
Andrew Monnich
22 Jan 24
4
Change in insider ownership
8 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.83 mm | 3.83 mm | 3.83 mm | 3.83 mm | 3.83 mm | 3.83 mm |
Cash burn (monthly) | 6.22 mm | 2.05 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 41.44 mm | 13.63 mm | n/a | n/a | n/a | n/a |
Cash remaining | -37.61 mm | -9.80 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | -6.0 | -4.8 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
92.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 119 |
Opened positions | 13 |
Closed positions | 9 |
Increased positions | 41 |
Reduced positions | 43 |
13F shares | Current |
---|---|
Total value | 504.76 bn |
Total shares | 22.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Amandla MK Trust | 5.34 mm | $217.68 mm |
Common Property Trust | 4.77 mm | $245.79 mm |
Kayne Anderson Rudnick Investment Management | 3.19 mm | $141.75 bn |
BLK Blackrock | 1.02 mm | $45.06 bn |
Vanguard | 980.69 k | $43.51 bn |
MS Morgan Stanley | 940.54 k | $41.73 bn |
Conestoga Capital Advisors | 773.22 k | $34.31 bn |
Dimensional Fund Advisors | 628.87 k | $27.90 bn |
QV Investors | 451.15 k | $20.02 mm |
Renaissance Technologies | 367.38 k | $16.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Nunnelly John N | Common Stock | Payment of exercise | Dispose F | No | No | 39.7 | 3,487 | 138.43 k | 32,666 |
27 Mar 24 | Nunnelly John N | Common Stock | Option exercise | Acquire M | No | No | 14.95 | 9,259 | 138.42 k | 36,153 |
27 Mar 24 | Nunnelly John N | Director Stock Option Common Stock | Option exercise | Dispose M | No | No | 14.95 | 9,259 | 138.42 k | 0 |
1 Mar 24 | Common Property Trust | Common Stock | Sell | Dispose S | Yes | No | 40.54 | 598,653 | 24.27 mm | 3,854,284 |
Press releases
National Research Corporation to Broadcast Its First Quarter 2024 Conference Call Live on the Internet
18 Apr 24
Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer
2 Apr 24
National Research Corporation Announces Fourth Quarter and Calendar Year 2023 Results
13 Feb 24
National Research Corporation to Broadcast Its Fourth Quarter and Year-end 2023 Conference Call Live on the Internet
1 Feb 24
NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions
1 Feb 24